Evidências científicas sobre o uso de novas drogas psicodélicas no tratamento da depressão resistente
Daiane Lima de Lara Ziles, Jigliane Tainã Macedo de Souza, Yoda Janaina Ikenohuchi, Vanessa Merlen Faleiros Ferraz de Sa
Revista fisio&terapia. June 25, 2026 Peer reviewed DOI: 10.69849/brj86f48 via OpenAlex
Summary
New psychedelic drugs show promise as therapeutic alternatives for resistant depression, a condition where many patients do not respond to standard treatments. A systematic review of literature from 2015 to 2025 will analyze clinical studies and trials to evaluate the efficacy, safety, and ethical considerations of these substances. The goal is to enhance understanding and support mental health professionals in exploring effective options for patients who struggle with conventional therapies.
Study at a glance
| Design | systematic review |
|---|---|
| Population | scientific articles on psychedelics for resistant depression |
| Key finding | The research aims to consolidate evidence on the efficacy and safety of psychedelics in treating resistant depression. |
Abstract
The treatment of resistant depression represents a significant challenge in psychiatry, as a considerable portion of patients do not adequately respond to conventional therapies. In this context, new psychedelic drugs have emerged as promising therapeutic alternatives, garnering increasing interest from the scientific and clinical community. The overall objective of this research is to analyze the scientific evidence regarding the efficacy and safety of using these substances in the treatment of resistant depression. To this end, a systematic literature review will be conducted, with search and critical analysis of recent scientific articles published between 2015 and 2025 in databases such as PubMed, SciELO, and Google Scholar. The methodology involves the selection of clinical studies, randomized controlled trials, and systematic reviews that address the neurobiological mechanisms, therapeutic outcomes, adverse effects, and ethical aspects involved in the use of psychedelics. It is expected that this research will contribute to the consolidation of scientific knowledge on the subject, presenting an integrated view of clinical advances and existing limitations, providing support for mental health professionals, researchers, and public policy makers. Furthermore, a critical analysis of the evidence may broaden the debate on effective alternatives for patients who do not respond to traditional treatments, in addition to promoting the destigmatization of the medicinal use of psychedelics and encouraging the adoption of evidence-based practices. Thereby, it is intended to contribute to the advancement of contemporary psychiatry, fostering the development of innovative and safe therapies that can improve the quality of life of patients with resistant depression.